FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joseph Jakubowski

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Blood Platelets

Concepts & Ideas

Living Beings

Procedures

Disorders

Coronary Artery Disease

Co-author Network

Publications

TOP 3
Joseph A Jakubowski; Stipo Jurcevic; D Richard Lachno; Timothy G Mant; Andrew L Frelinger; Jo Howard; David S Small; Kenneth J Winters; Chunmei Zhou; Christopher D Payne
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Ted Wun; Chunmei Zhou; Kenneth I Ataga; Andrew L Frelinger; Lori E Heath; Joseph A Jakubowski; Charles L Knupp; Lakshmanan Krishnamurti; Abdullah Kutlar; Lillian E McMahon; Enrico M Novelli; Chuke E Nwachuku; Jeffrey S Riesmeyer; Denis Soulieres; John J Strouse; Kenneth J Winters
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
M Urooj Zafar; S Elmariah; Valentin Fuster; C Giannarelli; Joseph A Jakubowski; C Santos-Gallego; S Sartori; David S Small; Juan F Viles-Gonzalez; David A Vorchheimer; Juan J Badimon
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joseph Jakubowski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Joseph A Jakubowski; Stipo Jurcevic; D Richard Lachno; Timothy G Mant; Andrew L Frelinger; Jo Howard; David S Small; Kenneth J Winters; Chunmei Zhou; Christopher D Payne
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
British journal of clinical pharmacology 2013;75(6):1433-44.
2013: Ted Wun; Chunmei Zhou; Kenneth I Ataga; Andrew L Frelinger; Lori E Heath; Joseph A Jakubowski; Charles L Knupp; Lakshmanan Krishnamurti; Abdullah Kutlar; Lillian E McMahon; Enrico M Novelli; Chuke E Nwachuku; Jeffrey S Riesmeyer; Denis Soulieres; John J Strouse; Kenneth J Winters
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Journal of hematology & oncology 2013;6(1):17.
2013: M Urooj Zafar; S Elmariah; Valentin Fuster; C Giannarelli; Joseph A Jakubowski; C Santos-Gallego; S Sartori; David S Small; Juan F Viles-Gonzalez; David A Vorchheimer; Juan J Badimon
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation.
Journal of thrombosis and haemostasis : JTH 2013;11(1):100-6.
2012: David Erlinge; David Foley; Joseph A Jakubowski; Stefan James; Junxiang Luo; Brian Moser; David S Small; Jurrien Ten Berg; Henrik Wagner; Dominick J Angiolillo; Thomas Bergmeijer; Patricia B Brown; Chunmei Zhou; Kenneth J Winters
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.
Journal of the American College of Cardiology 2012;60(20):2032-40.
2012: Joseph A Jakubowski; Amy G Leishman; Jeffrey S Riesmeyer; Sandra L Close; David Erlinge
TRITON and beyond: new insights into the profile of prasugrel.
Cardiovascular therapeutics 2012;30(4):e174-82.
2011: Joseph A Jakubowski; Ying G Li; Christopher D Payne; David S Small; Kenneth J Winters
Absence of "rebound" platelet hyperreactivity following cessation of prasugrel.
Thrombosis and haemostasis 2011;106(1):174-6.
2011: Baojin Zhu; Mark B Effron; M Pandurang Kulkarni; Ying G Li; Joseph A Jakubowski; Debra L Miller; Brian A Baker; Junxiang Luo; David S Small; Kenneth J Winters
The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Journal of cardiovascular pharmacology 2011;57(3):317-24.
2011: Joseph A Jakubowski
Beyond platelet functional testing: value in the aggregate.
Biomarkers in medicine 2011;5(1):5-8.
2011: Joseph A Jakubowski; Maya Kotob-Yahfoufi; Atsuhiro Sugidachi; Maggie Wells; Chunmei Zhou; Blaine Egan; Jeffrey R Dahlen
Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Platelets 2011;22(8):619-25.
2010: David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel Salazar
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Clinical pharmacokinetics 2010;49(12):777-98.
2010: H M Judge; S B Patil; R J Buckland; Joseph A Jakubowski; R F Storey
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.
Journal of thrombosis and haemostasis : JTH 2010;8(8):1820-7.
2010: Joseph A Jakubowski; Ying G Li; David S Small; Christopher D Payne; Molly E Tomlin; Junxiang Luo; Kenneth J Winters
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Journal of cardiovascular pharmacology 2010;56(1):29-37.
2010: David S Small; Christopher D Payne; Prajakti Kothare; Eunice Yuen; Fanni Natanegara; Mei Teng Loh; Joseph A Jakubowski; D Richard Lachno; Ying G Li; Kenneth J Winters; Nagy A Farid; Lan Ni; Daniel E Salazar; Molly Tomlin; Ronan Kelly
Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Clinical therapeutics 2010;32(2):365-79.
2010: David S Small; Prajakti Kothare; Eunice Yuen; D Richard Lachno; Ying G Li; Kenneth J Winters; Nagy A Farid; Lan Ni; Joseph A Jakubowski; Daniel Salazar; Vivian T Thieu; Christopher D Payne
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
European journal of clinical pharmacology 2010;66(2):127-35.
2009: Ying G Li; Lan Ni; John T Brandt; David S Small; Christopher D Payne; C Steven Ernest; Shashank Rohatagi; Nagy A Farid; Joseph A Jakubowski; Kenneth J Winters
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Platelets 2009;20(5):316-27.
2009: Nagy A Farid; Joseph A Jakubowski; Christopher D Payne; Y G Li; Y Jin; C S Ernest II; Kenneth J Winters; John T Brandt; Daniel Salazar; David S Small
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Current medical research and opinion 2009;25(8):1821-9.
2009: Taketoshi Ogawa; Masami Hashimoto; Yoichi Niitsu; Joseph A Jakubowski; Yoshiro Tani; Ken-ichi Otsuguro; Fumitoshi Asai; Atsuhiro Sugidachi
Effects of prasugrel, a novel P2Y(12) inhibitor, in rat models of cerebral and peripheral artery occlusive diseases.
European journal of pharmacology 2009;612(1-3):29-34.
2008: David Erlinge; Christoph Varenhorst; Oscar O Braun; Stefan James; Kenneth J Winters; Joseph A Jakubowski; John T Brandt; Atsuhiro Sugidachi; Agneta Siegbahn; Lars Wallentin
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Journal of the American College of Cardiology 2008;52(24):1968-77.
2008: Oscar O Braun; Matilda Johnell; Christoph Varenhorst; Stefan James; John T Brandt; Joseph A Jakubowski; Kenneth J Winters; Lars Wallentin; David Erlinge; Agneta Siegbahn
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Thrombosis and haemostasis 2008;100(4):626-33.
2008: Christopher D Payne; Ying G Li; John T Brandt; Joseph A Jakubowski; David S Small; Nagy A Farid; Daniel E Salazar; Kenneth J Winters
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.
Platelets 2008;19(4):275-81.
2008: Heather M Judge; Robert J Buckland; Atsuhiro Sugidachi; Joseph A Jakubowski; Robert F Storey
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Platelets 2008;19(2):125-33.
2008: Joseph A Jakubowski; Christopher D Payne; Ying G Li; John T Brandt; David S Small; Nagy A Farid; Daniel Salazar; Kenneth J Winters
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Thrombosis and haemostasis 2008;99(2):409-15.
2008: Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Matthew D Linden; I Tarnow; Marsha L Fox; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Journal of thrombosis and haemostasis : JTH 2008;6(2):359-65.
2008: Yoichi Niitsu; Atsuhiro Sugidachi; Taketoshi Ogawa; Joseph A Jakubowski; Masami Hashimoto; Takashi Isobe; Ken-ichi Otsuguro; Fumitoshi Asai
Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
European journal of pharmacology 2008;579(1-3):276-82.
2008: Ganesh R Sharma; Bruce Gerlitz; David T Berg; Martin S Cramer; Joseph A Jakubowski; Elizabeth Galbreath; Josef G Heuer; Brian W Grinnell
Activated protein C modulates chemokine response and tissue injury in experimental sepsis.
Advances in experimental medicine and biology 2008;614():83-91.
2008: Joseph A Jakubowski; Christopher D Payne; Ying G Li; Nagy A Farid; John T Brandt; David S Small; Daniel Salazar; Kenneth J Winters
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Thrombosis and haemostasis 2008;99(1):215-22.
2008: Lars Wallentin; Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; Joseph A Jakubowski; Atsuhiro Sugidachi; Kenneth J Winters; Agneta Siegbahn
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
European heart journal 2008;29(1):21-30.
2007: Stephen D Wiviott; Dietmar Trenk; Andrew L Frelinger; Michelle O'Donoghue; Franz-Josef Neumann; Alan D Michelson; Dominick J Angiolillo; Hanoch Hod; Gilles Montalescot; Debra L Miller; Joseph A Jakubowski; Richard Cairns; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Circulation 2007;116(25):2923-32.
2007: Joy K Saha; Jinqi Xia; George E Sandusky; Yun-Fei Chen; Bruce Gerlitz; Brian W Grinnell; Joseph A Jakubowski
Study of plasma protein C and inflammatory pathways: biomarkers for dimethylnitrosamine-induced liver fibrosis in rats.
European journal of pharmacology 2007;575(1-3):158-67.
2007: Christopher D Payne; Ying Grace Li; David S Small; C Steven Ernest; Nagy A Farid; Joseph A Jakubowski; John T Brandt; Daniel Salazar; Kenneth J Winters
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Journal of cardiovascular pharmacology 2007;50(5):555-62.
2007: Masami Hashimoto; Atsuhiro Sugidachi; Takashi Isobe; Yoichi Niitsu; Taketoshi Ogawa; Joseph A Jakubowski; Fumitoshi Asai
The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
Biochemical pharmacology 2007;74(7):1003-9.
2007: Govinda J Weerakkody; Joseph A Jakubowski; John T Brandt; Christopher D Payne; Hideo Naganuma; Kenneth J Winters
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
Journal of cardiovascular pharmacology and therapeutics 2007;12(3):205-12.
2007: Govinda J Weerakkody; John T Brandt; Christopher D Payne; Joseph A Jakubowski; Hideo Naganuma; Kenneth J Winters
Clopidogrel poor responders: an objective definition based on Bayesian classification.
Platelets 2007;18(6):428-35.
2007: Govinda J Weerakkody; Joseph A Jakubowski; John T Brandt; Nagy A Farid; Christopher D Payne; Jianyu Zhu; Margaret R Warner; Hideo Naganuma; Kenneth J Winters
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
The American journal of cardiology 2007;100(2):331-6.
2007: Andrew L Frelinger; Joseph A Jakubowski; Youfu Li; Marc R Barnard; Marsha L Fox; Matthew D Linden; Atsuhiro Sugidachi; Kenneth J Winters; Mark I Furman; Alan D Michelson
The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Thrombosis and haemostasis 2007;98(1):192-200.
2007: Atsuhiro Sugidachi; Taketoshi Ogawa; Atsushi Kurihara; K Hagihara; Joseph A Jakubowski; M Hashimoto; Y Niitsu; Fumitoshi Asai
The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Journal of thrombosis and haemostasis : JTH 2007;5(7):1545-51.
2007: Nagy A Farid; Christopher D Payne; David S Small; Kenneth J Winters; C Steven Ernest; John T Brandt; C Darstein; Joseph A Jakubowski; Daniel Salazar
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Clinical pharmacology and therapeutics 2007;81(5):735-41.
2007: Joseph A Jakubowski; Nobuko Matsushima; Fumitoshi Asai; Hideo Naganuma; John T Brandt; Takashi Hirota; Stephen Freestone; Kenneth J Winters
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
British journal of clinical pharmacology 2007;63(4):421-30.
2007: Joseph A Jakubowski; Christopher D Payne; Govinda J Weerakkody; John T Brandt; Nagy A Farid; Ying G Li; Hideo Naganuma; D Richard Lachno; Kenneth J Winters
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Journal of cardiovascular pharmacology 2007;49(3):167-73.
2007: Joseph A Jakubowski; Kenneth J Winters; Hideo Naganuma; Lars Wallentin
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Cardiovascular drug reviews 2007;25(4):357-74.
2007: John T Brandt; Christopher D Payne; Stephen D Wiviott; Govinda J Weerakkody; Nagy A Farid; David S Small; Joseph A Jakubowski; Hideo Naganuma; Kenneth J Winters
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
American heart journal 2007;153(1):66.e9-16.
2006: Nobuko Matsushima; Joseph A Jakubowski; Fumitoshi Asai; Hideo Naganuma; John T Brandt; Takashi Hirota; Stephen Freestone; Kenneth J Winters
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
Platelets 2006;17(4):218-26.
2006: Fumitoshi Asai; Joseph A Jakubowski; Hideo Naganuma; John T Brandt; Nobuko Matsushima; Takashi Hirota; Stephen Freestone; Kenneth J Winters
Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Platelets 2006;17(4):209-17.
2006: Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
European heart journal 2006;27(10):1166-73.
2006: Josef G Heuer; Ganesh R Sharma; Tonghai Zhang; Chunjin Ding; Dianna L Bailey; Eddie J Stephens; Kimberly C Holmes; Renee L Grubbs; Kelly A Fynboe; Yun-Fei Chen; Joseph A Jakubowski
Effects of hyperglycemia and insulin therapy on outcome in a hyperglycemic septic model of critical illness.
The Journal of trauma 2006;60(4):865-72.
2006: Joseph A Jakubowski; Christopher D Payne; John T Brandt; Govinda J Weerakkody; Nagy A Farid; David S Small; Hideo Naganuma; Grace Ying Li; Kenneth J Winters
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
Journal of cardiovascular pharmacology 2006;47(3):377-84.
2006: David T Berg; Bruce Gerlitz; Ganesh R Sharma; Mark A Richardson; Eddie J Stephens; Renee L Grubbs; Kimberly C Holmes; Kelly A Fynboe; Dominick Montani; Martin S Cramer; Steven D Engle; Joseph A Jakubowski; Josef G Heuer; Brian W Grinnell
FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis.
Clinical and vaccine immunology : CVI 2006;13(3):426-32.
2006: Joy K Saha; Jinqi Xia; Steven K Engle; Yun-Fei Chen; Wolfgang Glaesner; Joseph A Jakubowski
A model of controlled acute hyperglycemia in rats: Effects of insulin and glucagon-like peptide-1 analog.
The Journal of pharmacology and experimental therapeutics 2006;316(3):1159-64.
2005: Joy K Saha; Jinqi Xia; Janet M Grondin; Steven K Engle; Joseph A Jakubowski
Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models.
Experimental biology and medicine (Maywood, N.J.) 2005;230(10):777-84.
2005: Michihiro Hasegawa; Atsuhiro Sugidachi; Taketoshi Ogawa; Takashi Isobe; Joseph A Jakubowski; Fumitoshi Asai
Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Thrombosis and haemostasis 2005;94(3):593-8.
2005: Yoichi Niitsu; Joseph A Jakubowski; Atsuhiro Sugidachi; Fumitoshi Asai
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
Seminars in thrombosis and hemostasis 2005;31(2):184-94.
2004: Josef G Heuer; Dianna L Bailey; Ganesh R Sharma; Tonghai Zhang; Chunjin Ding; Amy Ford; Eddie J Stephens; Kimberly C Holmes; Renee L Grubbs; Kelly A Fynboe; Yun-Fei Chen; Joseph A Jakubowski
Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness.
The Journal of surgical research 2004;121(2):178-86.
2004: Josef G Heuer; Ganesh R Sharma; Bruce Gerlitz; Tonghai Zhang; Dianna L Bailey; Chunjin Ding; David T Berg; Douglas Perkins; Eddie J Stephens; Kimberly C Holmes; Renee L Grubbs; Kelly A Fynboe; Yun-Fei Chen; Brian W Grinnell; Joseph A Jakubowski
Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis.
Critical care medicine 2004;32(7):1570-8.
2002: Stanley J Marciniak; Mary Ann Mascelli; Mark I Furman; Alan D Michelson; Joseph A Jakubowski; Robert E Jordan; Peter J Marchese; Andrew L Frelinger
An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Thrombosis and haemostasis 2002;87(6):1020-5.